Title:
METHODS FOR THE TREATMENT OF SUBJECTS HAVING A HEPATITIS B VIRUS (HBV) INFECTION
Document Type and Number:
WIPO Patent Application WO/2018/195165
Kind Code:
A8
Abstract:
The present invention provides methods for the treatment of a subject having a Hepatitis B virus (HBV) infection, e.g., a chronic HBV infection, using a combination of an RNAi agent that targets HBV and an HBV vaccine. It is disclosed a RNAi agent and an HBV vaccine for use in treatment of HBV infection, comprising sequentially administering to the subject having an HBV infection: a) an RNAi agent that inhibits expression of at least three HBV transcripts, wherein the RNAi agent forms a double stranded region; b) a protein-based vaccine comprising a first HBV core antigen (HBcAg) polypeptide, and a first HBV surface antigen (HBsAg) polypeptide; and c) a nucleic acid-based vaccine comprising an expression vector construct encoding a second HBcAg polypeptide, and/or a second HBsAg polypeptide, wherein the second HBcAg polypeptide, and/or the second HBsAg polypeptide, shares at least one epitope with at least one of the first HBcAg polypeptide, and/or the first HBsAg polypeptide.
Inventors:
SEPP-LORENZINO LAURA (US)
PROTZER ULRIKE (DE)
MICHLER THOMAS (DE)
PROTZER ULRIKE (DE)
MICHLER THOMAS (DE)
Application Number:
PCT/US2018/028116
Publication Date:
November 22, 2018
Filing Date:
April 18, 2018
Export Citation:
Assignee:
ALNYLAM PHARMACEUTICALS INC (US)
UNIV MUENCHEN TECH (DE)
UNIV MUENCHEN TECH (DE)
International Classes:
A61K39/12; A61K31/713; A61K39/00; A61P31/20; C12N15/113; C12N15/86
Attorney, Agent or Firm:
SARGEANT, Brooke et al. (US)
Download PDF: